199171-93-2

Basic information

• Product Name: Benzoic acid, 3-nitro-4-propyl- (9CI)
• Synonyms: Benzoic acid, 3-nitro-4-propyl- (9CI)
• CAS NO: 199171-93-2
• Molecular Formula: C₁₀H₁₁NO₄
• Molecular Weight: 209.19864
• Product Categories: AMINOACID
• Mol File: 199171-93-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 347.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.282±0.06 g/cm3(Predicted)
• PKA: 3.66±0.10(Predicted)
• CAS DataBase Reference: Benzoic acid, 3-nitro-4-propyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-nitro-4-propyl- (9CI)(199171-93-2)
• EPA Substance Registry System: Benzoic acid, 3-nitro-4-propyl- (9CI)(199171-93-2)

Safety Data

• Hazardous Substances Data: 199171-93-2(Hazardous Substances Data)

Upstream product

• 2438-05-3 4-n-propylbenzoic acid 
• 2932-64-1 3-nitro-4-propyl-acetophenone 
• 2932-65-2 1-(4-propylphenyl)ethan-1-one 
• 103-65-1 phenylpropane 
• 857539-83-4 3-n-propylbenzoic acid 

Downstream Products

• 219763-95-8 6-carboxy-1-(2,4-dichlorobenzyl)-3-ethyl-1H-indazole 
• 24812-92-8 methyl 3-amino-4-propylbenzoate 

Relevant articles and documents

SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE (PDE) TYPE IV AND TUMOR NECROSIS FACTOR (TNF) INHIBITORS

The invention relates to compounds of the formula I and pharmaceutically acceptable salts thereof, wherein R, R1, and R2, are as defined herein. The invention further relates to pharmaceutical compositions containing, and methods of using, the compounds o

Sulfonamide compounds and medicinal use thereof

A sulfonamide compound of the formula (I):R 1 --SO 2 NHCO--A--R 2 (I)wherein R 1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

Substituted indazole derivatives and related compounds

The invention relates to compounds of the formula I and pharmaceutically acceptable salts thereof, wherein R2aand R2bare independently selected from the group consisting essentially of hydrogen and hereinafter recited substituents, provided that one, but not both of R2aand R2bmust be independently selected as hydrogen, wherein said substituents comprise: wherein the dashed lines in formulas (Ia) and (Ib) independently and optionally represent a single or double bond, provided that in formula (Ia) both dashed lines cannot both represent double bonds at the same time; and R, R1, R3, R4, R5, R6, R7, R18and m are as defined. The invention further relates to intermediates for the preparation of the compounds of formula I, and to pharmaceutical compositions containing, and methods of using, the compounds of formula I, or acceptable salts thereof, for the inhibition of phosphodiesterase (PDE) type IV or the production of tumor necrosis factor (TNF) in a mammal.